Compare Pepper Bio vs Recursion
Customers evaluate the quality of Pepper Bio's products using the following success metrics.
Overview
Pepper Bio is 6 yrs old and is based in United States.
Pepper Bio operates a drug discovery company. It provides actionable insight for drug research. It integrates phosphoproteomics, proteomics, transcriptomics, and genomics with a focus on neurodegenerative, inflammatory, and oncology therapeutics. The company was founded in 2018 and is based in Boston, Massachusetts.
Recursion is 11 yrs old and is based in United States.
Recursion (NASDAQ: RXRX) develops a clinical-stage biotechnology company. It combines experimental biology and automation with artificial intelligence (AI) in a parallel system to discover drugs for diverse indications such as genetic disease, inflammation, immunology, and infectious disease. It collaborates with biopharmaceutical companies to broadly explore diverse disease domains and identify novel therapeutic candidates. The company was founded in 2013 and is based in Salt Lake City, Utah.
Demo Video
Leadership
Jon Hu (Founder, Chief Executive Officer)
Christopher Gibson (Founder, Chief Executive Officer)
Funding
Product
Why Pepper Bio beats Recursion
- Global functional data via integration of phosphoproteomics provides us with a deep, mechanistic understanding of what’s going on. Recursion’s image-based approach will only capture results and not process. This difference allows Pepper to predict therapeutic responses in a more nuanced, comprehensive manner and ultimately results in drugs with better safety/efficacy profiles.
Information not available because Recursion has not claimed their profile.
Work for Recursion? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Recursion?
Claim your profile now.
Benefits
- Probability of success for programs we work on
- Novel target identified
- Novel MOA identified
Products
COMPASS Platform
Our bioplatform, COMPASS, uses proprietary lab methods and computational abilities to unlock a new level of sophistication in drug discovery. Like real-time navigation for drug discovery, we help partners find the safest, fastest route to new, effective drugs in clinical trials. So far, we have already identified applications of our technology for rare diseases in oncology, neurology, and inflammatory.
Customers
Pepper Bio works with 2 known companies.
Known Partners
Dean Felsher Laboratory, Cyclerion Therapeutics
Why They Buy
News & Analysis
Pepper Bio has not been mentioned in our research.
Recursion has been mentioned in our research 8 times.
Research Articles
Expert Collections
Digital Health
10,553 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
457 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
AI 100
299 items
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare